12
total announcements
CAPLIPOINT.NS · 15 min delayed
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the Exchange regarding 'Completion of Unannounced US FDA Inspection at the facility of Caplin Steriles Limited (Company's Subsidiary)'
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the Exchange about the transcript of the earnings call for Q1 FY 2026-27, available on the company's website.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the Exchange about the link of the recording of the earnings call for Q1 FY 2026-27, which was held on August 12, 2026.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the Exchange about Investor Presentation and announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company has also recommended a Final Dividend of Rs.4/- (200%) per equity share of Rs.2/- each for the financial year ended March 31, 2026.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company. The company has re-appointed Dr. Sridhar Ganesan as the Managing Director for a further period of two years and appointed Mr. D. Muralidharan as the Whole-Time Director for a period of two years, subject to the approval of Shareholders at the ensuing AGM.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and has recommended a final dividend of Rs. 4 per equity share for the financial year ended March 31, 2026.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has announced the record date for the purpose of dividend as September 18, 2026, in accordance with Regulation 42 of the SEBI Listing Regulations. The company's 35th Annual General Meeting will be held on September 25, 2026.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of Rs. 120.38 crores. The company has also recommended a final dividend of Rs. 4 per equity share and approved the re-appointment of Dr. Sridhar Ganesan as Managing Director and the appointment of Mr. D. Muralidharan as Whole-Time Director.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the Exchange about a post-results conference call with analysts and investors to discuss the financial performance for the quarter ended June 30, 2026.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, received from Integrated Registry Management Services Private Limited, the Registrar and Transfer Agent of the Company, for the quarter ended June 30, 2026.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, due to the finalization of unaudited Financial Results for the quarter ending June 30, 2026.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has informed the exchanges about the publication of newspaper advertisements regarding the transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF). This action is taken in accordance with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, and is a routine regulatory compliance disclosure.